Rallybio : RLYB116 Presentation

▪

▪

▪ ▪ ▪ ▪

RLYB116

•

•

•

AE preferred term			RLYB116			Placebo	All
						N=10	N=40
	2 mg	10 mg	30 mg	100 mg	300 mg
	n (%)	n (%)
	N=6	N=6	N=6	N=6	N=6
	n (%)	n (%)	n (%)	n (%)	n (%)
Gastrointestinal disorders
Abdominal pain/discomfort				2 (33.3)	2 (33.3)		4 (10.0)
Diarrhea	1 (16.7)			1 (16.7)	3 (50.0)	1 (10.0)	6 (15.0)
Nausea/Vomiting					2 (33.3)		2 (5.0)
General disorders and administration
Fatigue/Lethargy		1 (16.7)	1 (16.7)				2 (5.0)
Infections and infestations
COVID-19	1 (16.7)		1 (16.7)	1 (16.7)			3 (7.5)
Upper respiratory tract infection		1 (16.7)		1 (16.7)		1 (10.0)	3 (7.5)
Musculoskeletal and connective tissue
disorders
Back pain		2 (33.3)					2 (5.0)
Myalgia					1 (16.7)	1 (10.0)	2 (5.0)
Nervous system disorder
Dizziness/dizziness postural					2 (33.3)	1 (10.0)	3 (7.5)
Headache/migraine	1 (16.7)	1 (16.7)	2 (33.3)	1 (16.7)	2 (33.3)	2 (20.0)	9 (22.5)
Presyncope		1 (16.7)		1 (16.7)			2 (5.0)

1RLYB116 DSUR 2023

RLYB116

•

•

•

•